Use of hypnotic drugs among children, adolescents, and young adults in Scandinavia

Rikke Wesselhoeft*, Lotte Rasmussen, Peter Bjødstrup Jensen, Poul Jørgen Jennum, Svetlana Skurtveit, Ingeborg Hartz, Johan Reutfors, Per Damkier, Mette Bliddal, Anton Pottegård

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Background: Hypnotic use in children and adolescents is controversial. Objective: To describe the use of hypnotic drugs (melatonin, z-drugs, and sedating antihistamines) among 5- to 24-year-old Scandinavians during 2012 to 2018. Methods: Aggregate-level data were obtained from public data sources in Sweden, Norway, and Denmark. We calculated annual prevalence (users/1000 inhabitants) stratified by age group, sex, and country. Quantity of use (Defined Daily Dose (DDD)/user/day) was estimated for Norway and Denmark. Results: Melatonin was the most commonly used hypnotic, and its use increased markedly from 2012 to 2018, particularly among females and 15- to 24-year-old individuals. Sweden had the highest increase in use (6.5 to 25/1000) compared with Norway (10–20/1000) and Denmark (5.7–12/1000). The annual prevalence of sedating antihistamine use was also highest in Sweden, reaching 13/1000 in 2018 in comparison to 7.5/1000 in Norway and 2.5/1000 in Denmark. Z-drug use decreased in all countries toward 2018, dropping to 3.5/1000 in Sweden, 4.4/1000 in Norway, and 1.7/1000 in Denmark. The quantity of hypnotic use in Norway and Denmark was 0.8–1.0 DDD/user/day for melatonin in 2018, as compared to 0.1–0.3 for z-drugs and antihistamines. Conclusion: The use of melatonin and sedating antihistamines increased among young Scandinavians during 2012–2018, and the increase was twice as high in Sweden compared with Norway and Denmark. In addition, Sweden had the highest use of sedating antihistamines. The Scandinavian variation of hypnotic use could reflect differences in frequency of sleep problems between populations or variation of healthcare access or clinical practice between countries.

OriginalsprogEngelsk
TidsskriftActa Psychiatrica Scandinavica
Vol/bind144
Udgave nummer2
Sider (fra-til)100-112
ISSN0001-690X
DOI
StatusUdgivet - aug. 2021

Bibliografisk note

Funding Information:
Rikke Wesselhoeft and Mette Bliddal are funded in part by NIH R01MH114967.

Funding Information:
Anton Pottegård reports participation in research projects funded by Alcon, Almirall, Astellas, Astra‐Zeneca, Boehringer‐Ingelheim, Novo Nordisk, Servier, and LEO Pharma, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work reported in this paper. Johan Reutfors is employed at the Centre for Pharmacoepidemiology, Karolinska Institutet, which receives grants from several entities (pharmaceutical companies, regulatory authorities, and contract research organizations) for performance of drug safety and drug utilization studies, with no relation to the work reported in this paper. Rikke Wesselhoeft, Peter Bjødstrup Jensen, Mette Bliddal, Poul Jørgen Jennum, Svetlana Skurtveit, Ingeborg Hartz, and Per Damkier report no conflicts of interest.

Fingeraftryk

Dyk ned i forskningsemnerne om 'Use of hypnotic drugs among children, adolescents, and young adults in Scandinavia'. Sammen danner de et unikt fingeraftryk.

Citationsformater